Adaptive Historical Cash Flow
| ADPT Stock | USD 6.46 0.00 0.00% |
Analysis of Adaptive Biotechnologies cash flow over time is an excellent tool to project Adaptive Biotechnologies future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change To Inventory of 1.5 M or Investments of 30.3 M as it is a great indicator of Adaptive Biotechnologies ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Adaptive Biotechnologies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Adaptive Biotechnologies is a good buy for the upcoming year.
Adaptive |
About Adaptive Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Adaptive balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Adaptive's non-liquid assets can be easily converted into cash.
Adaptive Biotechnologies Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Adaptive Biotechnologies' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Adaptive Biotechnologies current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. At this time, Adaptive Biotechnologies' Change To Netincome is comparatively stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 7.0M | 11.6M | 30.0M | 31.5M | Depreciation | 14.0M | 20.9M | 22.2M | 13.4M |
Adaptive Biotechnologies cash flow statement Correlations
Click cells to compare fundamentals
Adaptive Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adaptive Biotechnologies cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 324.9M | 293.6M | 26.7M | 7.9M | 7.1M | 6.7M | |
| Change To Inventory | (1.2M) | (5.0M) | (5.2M) | 817K | 1.4M | 1.5M | |
| Investments | (470.5M) | (98.2M) | 243.0M | 2.9M | 28.9M | 30.3M | |
| Change In Cash | 43.6M | 26.9M | 15.6M | (48.8M) | (24.4M) | (23.2M) | |
| Stock Based Compensation | 13.1M | 24.8M | 43.3M | 55.5M | 62.9M | 34.2M | |
| Free Cash Flow | 194.2M | (168.5M) | (254.5M) | (200.3M) | (167.0M) | (158.7M) | |
| Change In Working Capital | 254.9M | (40.8M) | (56.8M) | (71.5M) | (46.2M) | (43.9M) | |
| Begin Period Cash Flow | 55.1M | 98.7M | 125.6M | 141.2M | 92.4M | 99.3M | |
| Total Cashflows From Investing Activities | (481.7M) | (117.0M) | 181.2M | 2.9M | 3.3M | 3.5M | |
| Other Cashflows From Financing Activities | (934K) | 21.4M | 27.1M | 7.9M | 2.2M | 2.1M | |
| Depreciation | 7.8M | 8.5M | 14.0M | 20.9M | 22.2M | 13.4M | |
| Other Non Cash Items | 43K | 3.3M | 7.0M | 11.6M | 30.0M | 31.5M | |
| Capital Expenditures | 11.2M | 18.8M | 61.7M | 16.3M | 10.7M | 20.1M | |
| Total Cash From Operating Activities | 205.4M | (149.7M) | (192.7M) | (183.9M) | (156.3M) | (148.5M) | |
| Change To Account Receivables | (7.8M) | 2.6M | (7.4M) | (22.6M) | 2.0M | 2.1M | |
| Change To Operating Activities | (9.1M) | (2.5M) | 9.5M | (330K) | (379.5K) | (398.5K) | |
| Net Income | (68.6M) | (146.2M) | (207.3M) | (200.4M) | (225.3M) | (214.0M) | |
| Total Cash From Financing Activities | 319.9M | 293.6M | 27.1M | 132.3M | 2.2M | 2.1M | |
| End Period Cash Flow | 98.7M | 125.6M | 141.2M | 92.4M | 68.0M | 104.7M | |
| Other Cashflows From Investing Activities | (470.5M) | (98.2M) | 181.2M | 19.3M | (1.0) | (1.05) | |
| Change To Netincome | 11.3M | 24.8M | 43.2M | 56.4M | 64.9M | 68.2M | |
| Change To Liabilities | 273.1M | 7.5M | 3.9M | 7.1M | 6.4M | 6.1M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.